Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2980281 | 0.93 | ITGB1 (0.52) | ITGB1ITGA4 | |
| SCHEMBL3836405 | 0.93 | ITGB1 (0.52) | ITGB1ITGA4 | |
| SCHEMBL3836469 | 0.92 | ITGB1 (0.51) | ITGB1ITGA4 | |
| SCHEMBL3832775 | 0.92 | ITGB1 (0.53) | ITGB1ITGA4 | |
| SCHEMBL3830914 | 0.91 | ITGB1 (0.51) | ITGB1ITGA4 | |
| SCHEMBL6131707 | 0.91 | ITGB1 (0.51) | ITGB1ITGA4 | |
| SCHEMBL3830919 | 0.91 | ITGB1 (0.51) | ITGB1ITGA4 | |
| SCHEMBL3834929 | 0.91 | ITGB1 (0.51) | ITGB1ITGA4 | |
| SCHEMBL2982569 | 0.90 | ITGB1 (0.50) | ITGB1ITGA4 | |
| SCHEMBL3837014 | 0.90 | ITGB1 (0.51) | ITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501437-B2 | Phenylalanine enamide derivatives | UCB PHARMA, S.A. (BE) | 2009-03-10 | — | — | US | disclosed |
| US-20070167483-A1 | 2-[(2-Isopropylsulfanyl-3-oxo-spiro[3.5]non-1-en-1-yl)amino]-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoic acid; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders | UCB PHARMA S.A. (BE) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167483-A1 | 2-[(2-Isopropylsulfanyl-3-oxo-spiro[3.5]non-1-en-1-yl)amino]-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoic acid; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders | ITGB2, VCAM1, ITGB1 | ITGB1 3/4885ITGA4 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.